Target Experimental data Clinical data
Ab (Mabthera)                CD20+ lymphocytes
Lymphoma
+ +
Immunotoxin (CAT-
3888, CAT- 8015)Antibody-drug conjugate (Brentuxi-mab)               
CD22+ lymphocytes
(Lymphoma, leukemia) CD30+ lymphocytes
(Hodgkin lymphoma)
+ + (+) (+)
Ab (HER2/neu)
Toxin (orellanine)
HER2+ tumor cells
Kidney cancer/tubulecells
+
+
+
-
Radiotherapy lymph nodes/lymphoma
Hodgkin’s disease    
+ +
Platinol Testicular cancer/
Teratoma
+ +
6-OH DOPA Melanoma + -
Ab (CTLA4)      T cell function
Autoimmune reaction
Melanoma, lung, kidney cancer
+ +
Ab (PD-1) T cell function
Autoimmune reaction
Melanoma, lung, kidney cancer
+ +
T-cell (transplantation) Leukemia
(graft vs. host)
+ +
Table 1: Examples of therapies that, either through experimental or clinical data, exploit the hypothesis that by injuring the cell of origin of the tumor, the tumor could also respond to therapy. Ab=antibody, + = positive relationship, (+)= studies underway, - = no studies performed yet .